PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$196.00

28 Oct
2026

-2.410

OPEN

$198.59

-1.21%

HIGH

$200.91

186,618

LOW

$194.55

TARGET
$225.833 15.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 254.0 195.2 xxx
DPS (cps) xxx 69.0 93.9 xxx
EPS Growth xxx 100.0% - 23.1% xxx
DPS Growth xxx 25.5% 36.1% xxx
PE Ratio xxx N/A 101.0 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 27.2% 48.1% xxx

Dividend yield today if purchased 3 years ago: 0.91%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.35

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 37.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx254.0
DPS All xxxxxxxxxxxxxxx69.0
Sales/Revenue xxxxxxxxxxxxxxx261.7 M
Book Value Per Share xxxxxxxxxxxxxxx431.6
Net Operating Cash Flow xxxxxxxxxxxxxxx136.5 M
Net Profit Margin xxxxxxxxxxxxxxx101.40 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx74.97 %
Return on Invested Capital xxxxxxxxxxxxxxx74.65 %
Return on Assets xxxxxxxxxxxxxxx55.93 %
Return on Equity xxxxxxxxxxxxxxx74.97 %
Return on Total Capital xxxxxxxxxxxxxxx55.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx71.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx251 M
Price To Book Value xxxxxxxxxxxxxxx47.13

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx3.32 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx189 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

19/08/2026

1

Buy

$230.00

17.35%

Ord Minnett points out FY26 results from Pro Medicus were a slight beat, with revenue better than consensus and underlying NPAT also a beat on market expectations.

Currency headwinds remained, but on a constant currency basis revenue rose 28% and NPAT up 33%. Post the final DPS of 37c, the total FY26 DPS at 69c is up 26%.

The broker points out shares have been heavily shorted (some 8% of the free float), which resulted in an outsized share price reaction to the results.

With only 11% market share of the radiology network, Ord Minnett believes there is significant scope for gains. Management hopes to target the "next 10%" in a faster time frame versus the "first 10%".

Target price rises to $230 from $210 with a Buy rating. The analyst highlights a robust pipeline of growth opportunities for the company and FY27 revenues already seem to be secured via existing contracts.

FORECAST
Ord Minnett forecasts a full year FY27 dividend of 91.00 cents and EPS of 182.00 cents.
Ord Minnett forecasts a full year FY28 dividend of 118.00 cents and EPS of 236.00 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

13/05/2026

1

Buy

$168.62

-13.97%

Canaccord Genuity maintains a Buy rating for Pro Medicus and reduces the target price to $168.62 from $180.82 following a review of the company's valuation relative to sector-wide multiple compression.

Revenue forecasts have been revised down by -8% for FY26 and -11% for FY27 to reflect lower data migration revenue and a higher AUD:USD exchange rate headwind.

The broker notes underlying fundamentals remain exceptional, with the business expected to deliver growth exceeding 20% on both the top and bottom lines despite negative sector sentiment.

Large contract wins yet to materialise in the profit and loss statement underpin significant earnings momentum for FY27 and FY28.

Mispricing is evident as market volatility masks the value of businesses with high excess cash returns, according to the report.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: A Tough Market, A Different Cycle

Oct 28 2026 - Rudi's View
2
Next Week At A Glance – 26-30 Oct 2026

Oct 23 2026 - Weekly Reports
3
Rudi’s View: Stocks To Own & Best To Avoid

Oct 15 2026 - Rudi's View
4
In Brief: Black Cat, Amplitude & Singular Health

Oct 02 2026 - Weekly Reports
5
Rudi’s View: Ampol, BlueScope, Evolution, Infratil, Ramelius & More

Sep 24 2026 - Rudi's View

Latest Medical Equipment & Devices News

1
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
2
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
3
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
4
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
5
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
6
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
7
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
8
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
9
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
10
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps